(-0.04%) 5 476.50 points
(-0.06%) 38 794 points
(0.01%) 19 922 points
(0.34%) $80.60
(1.29%) $2.82
(0.22%) $2 334.20
(-0.21%) $29.33
(-0.18%) $969.20
(0.01%) $0.932
(-0.16%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States...
Stats | |
---|---|
Šios dienos apimtis | 372 349 |
Vidutinė apimtis | 105 224 |
Rinkos kapitalizacija | 380.11M |
EPS | $-1.550 ( Q3 | 2023-11-13 ) |
Kita pelno data | ( $0 ) 2024-08-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-4.07 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0590 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-24 | Secor Alicia | Sell | 46 000 | Stock Option (Right to Buy) |
2024-01-24 | Secor Alicia | Sell | 105 000 | Stock Option (Right to Buy) |
2024-01-24 | Geraghty James A | Sell | 44 391 | Ordinary Shares |
2024-01-24 | Geraghty James A | Sell | 46 000 | Stock Option (Right to Buy) |
2024-01-24 | Geraghty James A | Sell | 105 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-40.97 |
Last 99 transactions |
Buy: 13 341 271 | Sell: 6 351 136 |
Tūris Koreliacija
Orchard Therapeutics PLC Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Orchard Therapeutics PLC Koreliacija - Valiuta/Žaliavos
Orchard Therapeutics PLC Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $6.99M |
Bruto pelnas: | $4.55M (65.17 %) |
EPS: | $-0.610 |
FY | 2022 |
Pajamos: | $6.99M |
Bruto pelnas: | $4.55M (65.17 %) |
EPS: | $-0.610 |
FY | 2021 |
Pajamos: | $1.68M |
Bruto pelnas: | $1.45M (86.51 %) |
EPS: | $-1.170 |
FY | 2020 |
Pajamos: | $2.60M |
Bruto pelnas: | $1.74M (66.97 %) |
EPS: | $-1.530 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Orchard Therapeutics PLC
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.